The laboratory results are consistent with the bioinformatics analysis results in terms of the impact of high SHMT2 expression on prognosis, which indicated that GC patients with high SHMT2 expression tended to have poor prognosis. This evidence concerns the gene SHMT2 and gastric cancer.